171 related articles for article (PubMed ID: 2104988)
1. TRH attenuates scopolamine-induced memory impairment in humans.
Molchan SE; Mellow AM; Lawlor BA; Weingartner HJ; Cohen RM; Cohen MR; Sunderland T
Psychopharmacology (Berl); 1990; 100(1):84-9. PubMed ID: 2104988
[TBL] [Abstract][Full Text] [Related]
2. Scopolamine effects on the pressor response to thyrotropin-releasing hormone in humans.
Molchan SE; Hill JL; Minichiello M; Vitiello B; Sunderland T
Life Sci; 1994; 54(13):933-8. PubMed ID: 8139380
[TBL] [Abstract][Full Text] [Related]
3. Caffeine attenuates scopolamine-induced memory impairment in humans.
Riedel W; Hogervorst E; Leboux R; Verhey F; van Praag H; Jolles J
Psychopharmacology (Berl); 1995 Nov; 122(2):158-68. PubMed ID: 8848531
[TBL] [Abstract][Full Text] [Related]
4. Effects of sustained release formulation of thyrotropin-releasing hormone on learning impairments caused by scopolamine and AF64A in rodents.
Miyamoto M; Hirai K; Takahashi H; Kato K; Nishiyama M; Okada H; Nagaoka A
Eur J Pharmacol; 1993 Jul; 238(2-3):181-9. PubMed ID: 8405091
[TBL] [Abstract][Full Text] [Related]
5. The effects of a benzodiazepine receptor antagonist beta-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills.
Duka T; Ott H; Rohloff A; Voet B
Psychopharmacology (Berl); 1996 Feb; 123(4):361-73. PubMed ID: 8867876
[TBL] [Abstract][Full Text] [Related]
6. The involvement of central cholinergic mechanisms in cardiovascular responses to intracerebroventricular and intravenous administration of thyrotropin-releasing hormone.
Okuda C; Mizobe T; Miyazaki M
Life Sci; 1987 Mar; 40(13):1293-9. PubMed ID: 3104710
[TBL] [Abstract][Full Text] [Related]
7. Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer's disease.
Mellow AM; Sunderland T; Cohen RM; Lawlor BA; Hill JL; Newhouse PA; Cohen MR; Murphy DL
Psychopharmacology (Berl); 1989; 98(3):403-7. PubMed ID: 2501817
[TBL] [Abstract][Full Text] [Related]
8. Scopolamine and benzodiazepine models of dementia: cross-reversals by Ro 15-1788 and physostigmine.
Preston GC; Ward C; Lines CR; Poppleton P; Haigh JR; Traub M
Psychopharmacology (Berl); 1989; 98(4):487-94. PubMed ID: 2570433
[TBL] [Abstract][Full Text] [Related]
9. NS-3(CG3703), a TRH analog, ameliorates scopolamine-induced memory disruption in rats.
Ogasawara T; Nakagawa Y; Ukai Y; Tamura M; Kimura K
Pharmacol Biochem Behav; 1995 Aug; 51(4):929-34. PubMed ID: 7675879
[TBL] [Abstract][Full Text] [Related]
10. Psychomotor, physiological and cognitive effects of scopolamine and ephedrine in healthy man.
Nuotto E
Eur J Clin Pharmacol; 1983; 24(5):603-9. PubMed ID: 6873137
[TBL] [Abstract][Full Text] [Related]
11. Central muscarinic cholinergic antagonists block wet-dog shakes produced by the TRH analog MK-771 in the rat.
Sills MA; Mellow AM; Sunderland T; Jacobowitz DM
Brain Res; 1988 Jun; 453(1-2):385-8. PubMed ID: 3135919
[TBL] [Abstract][Full Text] [Related]
12. The effects of thyrotropin-releasing hormone and scopolamine in Alzheimer's disease and normal volunteers.
Molchan SE; Mellow AM; Hill JL; Weingartner H; Martinez R; Vitiello B; Sunderland T
J Psychopharmacol; 1992 Jan; 6(4):489-500. PubMed ID: 22291397
[TBL] [Abstract][Full Text] [Related]
13. EEG and blood pressure effects of TRH in rabbits.
Beale JS; White RP; Huang SP
Neuropharmacology; 1977; 16(7-8):499-506. PubMed ID: 411053
[No Abstract] [Full Text] [Related]
14. [Effect of thyrotropin-releasing hormone (TRH) and its analog DN-1417 on scopolamine-induced impairment of short-term memory in rats].
Yamazaki N; Nagaoka A; Nagawa Y
Yakubutsu Seishin Kodo; 1986 Sep; 6(3):359-66. PubMed ID: 3101313
[TBL] [Abstract][Full Text] [Related]
15. The effect of centrally administered TRH on blood pressure, heart rate and ventilation in rat.
Koivusalo F; Paakkari I; Leppäluoto J; Karppanen H
Acta Physiol Scand; 1979 May; 106(1):83-6. PubMed ID: 111471
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological study of TA-0910, a new thyrotropin-releasing hormone (TRH) analog (IV): Effects on experimental memory impairment in mice and rats.
Yamamura M; Kinoshita K; Nakagawa H; Ishida R
Jpn J Pharmacol; 1991 Feb; 55(2):241-53. PubMed ID: 1906119
[TBL] [Abstract][Full Text] [Related]
17. Dose-specific effects of scopolamine on canine cognition: impairment of visuospatial memory, but not visuospatial discrimination.
Araujo JA; Chan AD; Winka LL; Seymour PA; Milgram NW
Psychopharmacology (Berl); 2004 Aug; 175(1):92-8. PubMed ID: 15029470
[TBL] [Abstract][Full Text] [Related]
18. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study.
Sunderland T; Tariot PN; Cohen RM; Weingartner H; Mueller EA; Murphy DL
Arch Gen Psychiatry; 1987 May; 44(5):418-26. PubMed ID: 3579494
[TBL] [Abstract][Full Text] [Related]
19. Serotonergic modulation of anticholinergic effects on cognition and behavior in elderly humans.
Little JT; Broocks A; Martin A; Hill JL; Tune LE; Mack C; Cantillon M; Molchan S; Murphy DL; Sunderland T
Psychopharmacology (Berl); 1995 Aug; 120(3):280-8. PubMed ID: 8524975
[TBL] [Abstract][Full Text] [Related]
20. Hemodynamic and neural mechanisms of action of thyrotropin-releasing hormone in the rat.
Sirén AL; Lake CR; Feuerstein G
Circ Res; 1988 Jan; 62(1):139-54. PubMed ID: 2891452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
